An oral medication, CT1812, is being investigated for the potential treatment of Dementia with Lewy Bodies (DLB). The purpose of this clinical trial is to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812. The study will also test how well CT1812 treats symptoms of mild to moderate DLB. Eligible participants will have a 2 out of 3 (66.6%) chance of receiving CT1812 and a 1 out of 3 (33.3%) chance of receiving placebo (sugar pill).

---

To be eligible for the 6-month study, the following criteria must be met:

• Must have a caregiver/ study partner 
• Willingness to undergo a lumbar puncture (LP) during the screening period and at the end of the 6-month treatment period.
• Formal education of eight or more years.
• Reside at home or in an assisted living facility.
• Must be able to complete all screening evaluations
• Must be between the ages of 50 and 85 and have a diagnosis of Dementia with Lewy Bodies. 

Contact the UNC study coordinator if you are interested in learning more about this study.